Cell collectionDay 0
Lab engineeringWeeks of processing
InfusionWeeks later
Cells are extracted, shipped, engineered and returned. Many patients can't afford to wait that long.
Reprogram the immune system. Inside the body.
Lumenra designs mRNA therapies that turn a patient's own immune cells into cancer-fighting cells - no extraction, no weeks of lab manufacturing, no waiting.
Backed by leading life science investors
Northwind Bio
Halcyon Capital
Meridian Life Sciences
Kestrel
Cobalt Health
Seastar Ventures
Juniper Fund
Ardent Bio Partners
Cell therapy works. Getting it to patients doesn't.
CAR-T has transformed blood cancer treatment. But today's process was built for the lab, not for the patient.
Custom batchOne per patient
Cold-chain shippingBoth directions
Quality releaseEvery single dose
Every dose is a custom production run. That makes it slow, fragile and hard to scale.
Specialized centersFew per region
Hospital stayOften required
Eligible patientsMany never treated
Only a handful of specialized centers can deliver it. Most patients who could benefit never get the chance.
One infusion. Your cells do the rest.
Our LumenOS platform combines AI-driven molecular design with targeted delivery to engineer immune cells where they already live.
Platform '26LumenOS
Stage 1 / 6
Starting with blood cancers. Built for much more.
Drag to explore our programs
Let's bring cell therapy to every patient who needs it.
We're partnering with pharma companies, clinical sites and investors who share our mission to make cell therapy fast, scalable and accessible.